Specifically, NUTM2A/B represent frequent fusion partners in subsets of high‐grade endometrial stromal sarcoma (ESS) [1], clear cell sarcoma of the kidney [2], CIC‐rearranged sarcomas [3], and emerging primitive undifferentiated pediatric sarcomas [4, 5]. This evidence concerns the gene NUTM2A and endometrioid stromal sarcoma.